Nature journal: a new method for the treatment of brain metastasis of cancer by continuously delivering monoclonal antibodies to the central nervous system

August 14, 2019 news / BIOON / - about 15-40% of cancers will metastasize in the central nervous system (CNS), but there is almost no treatment at present Monoclonal antibody based cancer therapy is widely successful, but because of the low level of drug reaching the tumor site, the curative effect on central nervous system metastasis is limited In order to enhance the therapeutic effect of clonal antibody on brain metastasis, Yunfeng Lu, Irvin S y Chen and Masakazu from UCLA recently Professor Kamata has developed a new method of polymer encapsulated antibody to achieve the sustained release of drugs from brain metastases, thus enhancing the efficacy of antibody in the treatment of brain metastases Relevant research results are published in nature biological engineering, entitled "sustained delivery and molecular targeting of a thermal monoclonal antibody to metals in the central nervous system of mice"。 Photo source: nature biomedical engineering in this study, researchers wrapped rituximab in the cross-linked amphoteric polymer layer As the cross-linking agent gradually hydrolyzed, the release of rituximab continued Compared with the free rituximab, the antibody level in CNS increased about 10 times The researchers found that after modifying CXCL13 (CXCR5 chemokine receptor ligand, often found on the surface of B-cell lymphoma) with this nanocapsule, one injection could improve the control of cvxr5 positive metastasis of non Hodgkin's lymphoma and eliminate the lymphoma of xenogeneic human marrow liver thymus mouse model This study suggests that the encapsulation and molecular targeting of therapeutic antibodies may be an option for the treatment of central nervous system metastasis Reference: Masakazu Kamata et al Sustained delivery and molecular targeting of a thermal monoclonal anomaly to metals in the central nervous system of mice Nature Biological Engineering (2019) DOI https://doi.org/10.1038/s41551-019-0434-z